Jinling Pharmaceutical (000919.SZ) subsidiary's arotinolol hydrochloride API approved for marketing.
Jinling Pharmaceutical (000919.SZ) announced that its controlling subsidiary, Chizhou Dongsheng Pharmaceutical Co., Ltd., recently received the "Chemical API Marketing Application Approval Notice" for arotinolol hydrochloride issued by the National Medical Products Administration. Arotinolol hydrochloride is a receptor blocker that blocks both alpha and beta receptors, and its formulation products are mainly used to treat essential hypertension (mild to moderate), angina pectoris, and other diseases.
Jinling Pharmaceutical (000919.SZ) announced that its controlling subsidiary, Chizhou Dongsheng Pharmaceutical Co., Ltd., recently received the "Marketing Application Approval Notice for Chemical Active Pharmaceutical Ingredients" for arotinolol hydrochloride issued by the National Medical Products Administration. Arotinolol hydrochloride is a receptor blocker that blocks both alpha and beta receptors, and its formulation products are mainly used to treat essential hypertension (mild to moderate), angina pectoris, and other diseases.
Related Articles
SUNAC SERVICES (01516) repurchased 300,000 shares for HK$229,800 on September 23.
CIMC ENRIC (03899) repurchased 200,000 shares for approximately HK$1.4291 million on September 23.
BESTSTUDY EDU (03978) repurchased 246,000 shares for HK$610,200 on September 23.
SUNAC SERVICES (01516) repurchased 300,000 shares for HK$229,800 on September 23.
CIMC ENRIC (03899) repurchased 200,000 shares for approximately HK$1.4291 million on September 23.
BESTSTUDY EDU (03978) repurchased 246,000 shares for HK$610,200 on September 23.
